Aktuelle Aspekte der medikamentösen kardiovaskulären Sekundärprävention

Einleitung

Basis aller Maßnahmen zur Behandlung arteriosklerotisch bedingter kardiovaskulärer Erkrankungen und prognostisch von herausragender Bedeutung ist die Anpassung des Lebensstils. Auf dieser Basis lässt sich die Langzeitprognose durch die moderne Pharmakotherapie zusätzlich signifikant verbessern. Prognostisch relevant ist vor allem die Therapie mit Acetylsalicylsäure (plus Clopidogrel bei gezielter Indikation), Betablockern, ACE-Hemmern oder Angiotensin-Rezeptorenblockern und Statinen. In besonderen Fällen (nach Herzinfarkt und bei schwerer Herzinsuffizienz) trifft dies auch für Aldosteronantagonisten zu.

Literatur

• 1 Heidrich J, Liese A D, Kalic M. et al . Sekundärprävention der koronaren Herzkrankheit - Ergebnisse der Euroaspire I- und II-Studien in der Region Münster, Germany. Secondary prevention of coronary heart disease. Results from EuroASPIRE I and II in the region Munster, Germany.  DMW. 2002;  127 667-672
• 2 Jost A, Rauch B, Hochadel M. et al . Beta-blocker treatment of patients with chronic systolic heart failure improves prognosis even in patients meeting one or more exclusion criteria of the MERIT-HF study.  Eur Heart J. 2005;  26 2689-2697
• 3 MERIT-HF Study Group . Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF).  Lancet. 1999;  353 2001-2007
• 4 Bertrand M E, Simoons M C, Fox K. et al . Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology.  Eur Heart J. 2002;  23 1809-1840
• 5 Hunt S A, Baker D W, Chin M H. et al . ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure).  Circulation. 2001;  104 2996-3007
• 6 Leon A S, Franklin B A, Costa F. et al . Cardiac Rehabilitation and Secondary Prevention of Coronary Heart Disease. An American Heart Associations Scientific Statement From the Counsil on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation and Prevention) and the Counsil on Nutrition, Physical Activity, and Metabolism (Subcommitte on Physical Activity), in Collaboration with the American Association of Cardiovascular and Pulmonary Rehabilitation.  Circulation. 2005;  111 369-376
• 7 Swedberg K, Metra M, Cleland J. Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. . Guidelines for the diagnosis and treatment of chronic heart failure.  Eur Heart J. 2005;  26 1115-1140
• 8 Williams M A, Fleg J L, Ades P A. et al . Secondary prevention of coronary heart disease in the elderly (with emphasis on patients ≥ 75 years of age): an American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac rehabilitation, and Prevention.  Circulation. 2002;  105 1735-1743
• 9 Verschuren W M, Jacobs D R, Bloemberg B P. et al . Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study.  JAMA. 1995;  274 131-136
• 10 Cullen P, Funke H, Schulte H, Assmann G. Lipoproteins and cardiovascular risk - from genetics to CHD prevention.  Eur Heart J. 1998;  19 (Suppl C) C5-C11
• 11 LaRosa J C, He J, Vupputuri S. Effect of Statins on Risk of Coronary Disease - a metaanalysis of randomized controlled trials.  JAMA. 1999;  282 2340-2346
• 12 LaRosa J C, Grundy S M, Waters D D. et al . for the Treating to New Targets (TNT) Investigators. Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease.  New Engl J Med. 2005;  352 1425-1435
• 13 Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. Non-lipid-related effects of statins.  Ann Med. 2000;  32 164-176
• 14 Jochmann N, Stangl K, Garbe E, Baumann G, Stangl V. Female-specific aspects in the phyarmacotherapy of chronic cardiovascular diseases.  Eur Heart J. 2005;  26 1585-1595
• 15 Van den Hoogen P C, Feskens E J, Nagelkerke N J, Menotti A, Nissinen A, Kromhout D. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven countries study research group.  New Engl J Med. 2000;  342 1-8
• 16 Franco V, Oparil S, Carretero O A. Hypertensive Therapy: Part II.  Circulation. 2004;  109 3081-3088
• 17 European Society of Hypertension . European Society of Hypertension - European Society of Cardiology Guidelines for the Management of Arterial Hypertension.  J Hypertens. 2003;  21 1011-1053
• 18 Franco V, Oparil S, Carretero O A. Hypertensive Therapy: Part I.  Circulation. 2004;  109 2953-2958
• 19 Dahlöf B, Sever P S, Poulter N R. et al . Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outsomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial.  Lancet. 2005;  366 895-906
• 20 Wachtell K, Lehto M, Gerdts E. et al . Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol. The Losartan Intervention For End point reduction in hypertension (LIFE) study.  J Am Coll Cardiol. 2005;  45 712-719
• 21 UK Prospective Diabetes Study Group . UKPDS 39. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39.  BMJ. 1998;  317 713-720
• 22 Tabacova S, Little R, Tsong Y, Vega A, Kimmel C A. Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment.  Pharmacoepidemiology and drug safety. 2003;  12 633-646
• 23 Grundy S M, Benjamin E J, Burke G L. et al . Diabetes and Cardiovascular Disease. A Statement for healthcare Professionals From the American Heart Association.  Circulation. 1999;  100 1134-1146
• 24 Standl E, Eckert S, Fuchs C. et al .Diabetes-Leitlinie (DDG) „Diabetes und Herz”. 2002
• 25 Dormandy J A, Charbonnel B, Eckland D JA. et al for the PROactive investigators . Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective piogliAzone Clinical Trial In macroVascular Events): a randomized controlled trial.  Lancet. 2005;  366 1279-1289
• 26 Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven longterm studies.  Eur Heart J. 2004;  25 10-16
• 27 Gelfand E V, Cannon C P. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors.  J Am Coll Cardiol. 2006;  47 1919-1926
• 28 Kyrou I, Valsamakis G, Tsigos C. The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome.  Annals of the New York Academic of Sciences. 2006;  1083 270-305
• 29 Hoppe U C, Erdmann E.. Vorstand der Deutschen Gesellschaft für Kardiologie- Herz- und Kreislaufforschung (Hrsg), bearbeitet im Auftrag der Kommission für Klinische Kardiologie in Zusammenarbeit mit der Arzneimittelkommission der Deutschen Ärzteschaft . Leitlinien zur Therapie der chronischen Herzinsuffizienz.  Z Kardiol. 2001;  90 218-237
• 30 Fox K A, Mehta S R, Peters R. et al . Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.  Circulation. 2004;  110 1202-1208
• 31 Masoudi F A, Havranek E P, Smith G. et al . Gender, age, and heart failure with preserved left ventricular sysolic function.  J Am Coll Cardiol. 2003;  41 217-223
• 32 Hulley S, Grady D, Bush T. et al . Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and estrogen/progestin Replacement Study (HERS) Research Group.  JAMA. 1998;  280 605-613
• 33 Waters D D, Alderman E I, Haia J. et al . Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial.  JAMA. 2002;  288 2432-2440
• 34 Erstpublikation in: Rauch B et al. Kardiologische Rehabilitation.  Thieme. 2007;